Relmada Therapeutics RLMD Earnings Call Transcripts

NASDAQ RLMD
$4.27 +0.13 (+3.14%)
At close: Nov 10, 2026 · 4:00 PM EST
3 earnings calls on file for Relmada Therapeutics, from Q3 2025 to Q2 2026. Each transcript opens in a new tab.
Latest earnings call

Relmada Therapeutics Q2 2026 Earnings Call

Aug 6, 2026 3,779 words · 16 min read
  • Sergio TraversaChief Executive Officer
  • Bipin DalmiaChief Business Officer
  • Maged ShenoudaChief Financial Officer
  • Joyce LonerganInvestor Relations
Prepared remarks and the full analyst Q&A, speaker by speaker.
Earnings calls

Relmada Therapeutics Earnings Call Transcripts

Calls3
LatestAug 6, 2026
SinceQ3 2025

Fiscal 2026

Fiscal 2025

All 3 Relmada Therapeutics transcripts Register to get access to Relmada Therapeutics’s earnings call transcripts.